Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

Hypertension-Pipeline Review H1 2017

 



(Medical-NewsWire.com, June 20, 2017 ) Hypertension, also referred to as high blood pressure, is a condition in which the arteries have persistently elevated blood pressure. Many factors can affect blood pressure, including hormone levels, water and salt levels in body and condition of kidneys, nervous system, or blood vessels. Most people with high blood pressure have no signs or symptoms, even if blood pressure readings reach dangerously high levels. Although a few people with early-stage high blood pressure may have dull headaches, dizzy spells or a few more nosebleeds than normal, these signs and symptoms typically don't occur until high blood pressure has reached a severe.



Report Highlights



Pharmaceutical and Healthcare latest pipeline guide Hypertension - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hypertension (Cardiovascular) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.



The Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 35, 35, 31, 89, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 24 and 11 molecules, respectively.



Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.





For more information about this report at http://www.reportsweb.com/hypertension-pipeline-review-h1-2017



Report Scope



- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertension (Cardiovascular) .

- The pipeline guide reviews pipeline therapeutics for Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hypertension (Cardiovascular)



Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834389/sample



Reasons to buy



- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypertension (Cardiovascular) .

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Key Company profiles

A1M Pharma AB

Actelion Ltd

Alnylam Pharmaceuticals Inc

Anacor Pharmaceuticals Inc

AnGes MG Inc

Arena Pharmaceuticals Inc

Ascendis Pharma A/S

Asklepion Pharmaceuticals LLC

AVEO Pharmaceuticals Inc

Bayer AG

Bial - Portela & Ca SA

Biolab Farmaceutica Ltda

BioRestorative Therapies Inc

Boryung Pharmaceutical Co Ltd

Bristol-Myers Squibb Company

Camurus AB

Capricor Therapeutics Inc

Celsion Corp

Celtaxsys Inc

Chiesi Farmaceutici SpA

Chong Kun Dang Pharmaceutical Corp

CJ HealthCare Corp

Conatus Pharmaceuticals Inc

Corion Biotech Srl

Cumberland Pharmaceuticals Inc

Cytokinetics Inc

Daewoong Co Ltd

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Company Ltd

DiaMedica Therapeutics Inc

Eli Lilly and Company

Esperion Therapeutics Inc

F. Hoffmann-La Roche Ltd

Ferring International Center SA

Galectin Therapeutics Inc

Gemphire Therapeutics Inc

Gilead Sciences Inc

GlaxoSmithKline Plc

H. Lundbeck A/S

HanAll Biopharma Co Ltd

Hanmi Pharmaceuticals Co Ltd

HitGen LTD

Innopharmax Inc

Insmed Inc

Insys Therapeutics Inc

Ionis Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Jeil Pharmaceutical Co Ltd

Johnson & Johnson

JW Pharmaceutical Corp

Kowa Company Ltd

Leading BioSciences Inc

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

LinXis BV

Liquidia Technologies Inc

Lotus Pharmaceutical Co Ltd

MannKind Corp

Marina Biotech Inc

Merck & Co Inc

Mezzion Pharma Co Ltd

Mitsubishi Tanabe Pharma Corp

Nanoform Cardiovascular Therapeutics Ltd

Neurim Pharmaceuticals Ltd

Nippon Kayaku Co Ltd

Nippon Shinyaku Co Ltd

Northern Therapeutics Inc

Novartis AG

Noxamet Ltd

Omeros Corp

Peloton Therapeutics Inc

Pfizer Inc

PhaseBio Pharmaceuticals Inc

Pluristem Therapeutics Inc

Polyphor Ltd

Pulmokine Inc

Quantum Genomics SA

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

Relypsa Inc

Renova Therapeutics Inc

Respira Therapeutics Inc

Reviva Pharmaceuticals Inc

rEVO Biologics Inc

Rottapharm Biotech Srl

Sanofi

Savara Inc

Serodus ASA

Shanghai Pharmaceutical Co Ltd

Silence Therapeutics Plc

Simcere Pharmaceutical Group

SteadyMed Therapeutics Inc

Suda Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Company Ltd

The Medicines Company

Theravance Biopharma Inc

Toray Industries Inc

Torrent Pharmaceuticals Ltd

TSH Biopharm Corporation Ltd

United Therapeutics Corp

Vascular BioSciences

Vectura Group Plc

VG Life Sciences Inc

Vicore Pharma AB

Vivus Inc

XORTX Pharma Corp

XuanZhu Pharma Co Ltd

Yuhan Corp





Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834389/discount





List of Tables



Number of Products under Development for Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1) , H1 2017

Products under Development by Companies, H1 2017 (Contd..2) , H1 2017

Products under Development by Companies, H1 2017 (Contd..3) , H1 2017

Products under Development by Companies, H1 2017 (Contd..4) , H1 2017

Products under Development by Companies, H1 2017 (Contd..5) , H1 2017

Products under Development by Companies, H1 2017 (Contd..6) , H1 2017

Products under Development by Companies, H1 2017 (Contd..7) , H1 2017

Products under Development by Companies, H1 2017 (Contd..8) , H1 2017

Products under Development by Companies, H1 2017 (Contd..9) , H1 2017

Products under Development by Companies, H1 2017 (Contd..10) , H1 2017

Products under Development by Companies, H1 2017 (Contd..11) , H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Hypertension - Pipeline by A1M Pharma AB, H1 2017

Hypertension - Pipeline by Actelion Ltd, H1 2017

Hypertension - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Anacor Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by AnGes MG Inc, H1 2017

Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017

Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017

Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Bayer AG, H1 2017

Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017

Hypertension - Pipeline by Biolab Farmaceutica Ltda, H1 2017

Hypertension - Pipeline by BioRestorative Therapies Inc, H1 2017

Hypertension - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017

Hypertension - Pipeline by Bristol-Myers Squibb Company, H1 2017

Hypertension - Pipeline by Camurus AB, H1 2017

Hypertension - Pipeline by Capricor Therapeutics Inc, H1 2017

Hypertension - Pipeline by Celsion Corp, H1 2017

Hypertension - Pipeline by Celtaxsys Inc, H1 2017

Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017

Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017

Hypertension - Pipeline by CJ HealthCare Corp, H1 2017

Hypertension - Pipeline by Conatus Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Corion Biotech Srl, H1 2017

Hypertension - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Cytokinetics Inc, H1 2017

Hypertension - Pipeline by Daewoong Co Ltd, H1 2017

Hypertension - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017

Hypertension - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Hypertension - Pipeline by DiaMedica Therapeutics Inc, H1 2017

Hypertension - Pipeline by Eli Lilly and Company, H1 2017

Hypertension - Pipeline by Esperion Therapeutics Inc, H1 2017

Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Hypertension - Pipeline by Ferring International Center SA, H1 2017

Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017

Hypertension - Pipeline by Gemphire Therapeutics Inc, H1 2017

Hypertension - Pipeline by Gilead Sciences Inc, H1 2017

Hypertension - Pipeline by GlaxoSmithKline Plc, H1 2017

Hypertension - Pipeline by H. Lundbeck A/S, H1 2017

Hypertension - Pipeline by HanAll Biopharma Co Ltd, H1 2017

Hypertension - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Hypertension - Pipeline by HitGen LTD, H1 2017

Hypertension - Pipeline by Innopharmax Inc, H1 2017

Hypertension - Pipeline by Insmed Inc, H1 2017

Hypertension - Pipeline by Insys Therapeutics Inc, H1 2017

Hypertension - Pipeline by Ionis Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017

Hypertension - Pipeline by Johnson & Johnson, H1 2017

Hypertension - Pipeline by JW Pharmaceutical Corp, H1 2017

Hypertension - Pipeline by Kowa Company Ltd, H1 2017

Hypertension - Pipeline by Leading BioSciences Inc, H1 2017

Hypertension - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Hypertension - Pipeline by Les Laboratoires Servier SAS, H1 2017

Hypertension - Pipeline by LinXis BV, H1 2017

Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017

Hypertension - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Hypertension - Pipeline by MannKind Corp, H1 2017

Hypertension - Pipeline by Marina Biotech Inc, H1 2017

Hypertension - Pipeline by Merck & Co Inc, H1 2017

Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017

Hypertension - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2017

Hypertension - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2017

Hypertension - Pipeline by Neurim Pharmaceuticals Ltd, H1 2017

Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017

Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017

Hypertension - Pipeline by Novartis AG, H1 2017

Hypertension - Pipeline by Noxamet Ltd, H1 2017

Hypertension - Pipeline by Omeros Corp, H1 2017

Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017

Hypertension - Pipeline by Pfizer Inc, H1 2017

Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017

Hypertension - Pipeline by Polyphor Ltd, H1 2017

Hypertension - Pipeline by Pulmokine Inc, H1 2017

Hypertension - Pipeline by Quantum Genomics SA, H1 2017

Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by RedHill Biopharma Ltd, H1 2017

Hypertension - Pipeline by Relypsa Inc, H1 2017

Hypertension - Pipeline by Renova Therapeutics Inc, H1 2017

Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017

Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Hypertension - Pipeline by rEVO Biologics Inc, H1 2017

Hypertension - Pipeline by Rottapharm Biotech Srl, H1 2017

Hypertension - Pipeline by Sanofi, H1 2017

Hypertension - Pipeline by Savara Inc, H1 2017

Hypertension - Pipeline by Serodus ASA, H1 2017

Hypertension - Pipeline by Shanghai Pharmaceutical Co Ltd, H1 2017

Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017

Hypertension - Pipeline by Simcere Pharmaceutical Group, H1 2017

Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017

Hypertension - Pipeline by Suda Ltd, H1 2017

Hypertension - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Hypertension - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Hypertension - Pipeline by The Medicines Company, H1 2017

Hypertension - Pipeline by Theravance Biopharma Inc, H1 2017

Hypertension - Pipeline by Toray Industries Inc, H1 2017

Hypertension - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Hypertension - Pipeline by TSH Biopharm Corporation Ltd, H1 2017

Hypertension - Pipeline by United Therapeutics Corp, H1 2017

Hypertension - Pipeline by Vascular BioSciences, H1 2017

Hypertension - Pipeline by Vectura Group Plc, H1 2017

Hypertension - Pipeline by VG Life Sciences Inc, H1 2017

Hypertension - Pipeline by Vicore Pharma AB, H1 2017

Hypertension - Pipeline by Vivus Inc, H1 2017

Hypertension - Pipeline by XORTX Pharma Corp, H1 2017

Hypertension - Pipeline by XuanZhu Pharma Co Ltd, H1 2017

Hypertension - Pipeline by Yuhan Corp, H1 2017

Hypertension - Dormant Projects, H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..1) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..2) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..3) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..4) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..5) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..6) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..7) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..8) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..9) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..10) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..11) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..12) , H1 2017

Hypertension - Dormant Projects, H1 2017 (Contd..13) , H1 2017

Hypertension - Discontinued Products, H1 2017

Hypertension - Discontinued Products, H1 2017 (Contd..1) , H1 2017



Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834389/buy/2000



ReportsWeb.com

Priya Sisodia

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC